A 3 million-plus patient longitudinal study found the drug class was no worse for amputation risks than other diabetes therapies, despite recent conflicting studies.
Patrick Campbell & Kevin Kunzmann
Advertisement
Articles by Patrick Campbell & Kevin Kunzmann
Advertisement
Latest Updated Articles
Diabetes Amputation Risk Not Worsened by SGLT-2 InhibitorsMarch 17th 2019
Advertisement
Advertisement
Trending on HCPLive
1
Diabetes Technology at a Turning Point: What’s New and What’s Next, With Rachael Sood, NP
2
ACCESS: Aleniglipron Achieves Up To 11.3% Weight Loss in Phase 2b Obesity Trial
3
Machine Learning Model Predicts Type 2 Diabetes Risk Up To 10 Years Out
4
5 Allergy Headlines You Missed in May 2026
5